MIRANasdaq

MIRA PHARMACEUTICALS, INC.

Healthcare·Neurology·Commercial·Miami, FL, United States
NeurologyMetabolicPainPsychiatry

MIRA PHARMACEUTICALS, INC. (MIRA): 3 pipeline candidates · ~23 mo cash runway · 3 clinical trials. Updated within the last hour.

6.6/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway6.4

22.9 months

Financial Health10.0

D/E 0.01 · 0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for MIRA PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$39.2M

Cash

$4.8M

Quarterly Burn

$1.2M

Runway

22.9 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2028
Today~25 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

25

Total value held

$2.9M

HolderSharesValue
vanguard capital management llc1,387,824$1.5M
cross staff investments inc359,401$385K
geode capital management, llc290,890$311K
vanguard fiduciary trust co169,483$181K
blackrock, inc.112,346$120K
northern trust corp67,698$72K
first american bank60,000$64K
state street corp49,100$53K
xtx topco ltd37,573$40K
commonwealth equity services, llc35,067$38K

Showing top 10 of 25 institutional holders of MIRA PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·CEO: Mr. Erez Aminov

Frequently asked questions

How many drug candidates are in MIRA PHARMACEUTICALS, INC.'s pipeline?

MIRA PHARMACEUTICALS, INC. (MIRA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is MIRA PHARMACEUTICALS, INC.'s lead drug candidate?

MIRA PHARMACEUTICALS, INC.'s most advanced tracked candidate is ketamir-2 (Phase 1) for diabetic neuropathy, neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

What is MIRA PHARMACEUTICALS, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, MIRA PHARMACEUTICALS, INC. has approximately 22.9 months of cash runway.

What is MIRA PHARMACEUTICALS, INC.'s market capitalization?

MIRA PHARMACEUTICALS, INC.'s market capitalization is approximately $39.2M.

Who is the CEO of MIRA PHARMACEUTICALS, INC.?

Mr. Erez Aminov is the chief executive officer of MIRA PHARMACEUTICALS, INC. (MIRA).

Get the full picture on MIRA PHARMACEUTICALS, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.